A Phase II Uncontrolled Study of BAY 73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer ( RCC)

Trial Profile

A Phase II Uncontrolled Study of BAY 73-4506 in Previously Untreated Patients With Metastatic or Unresectable Renal Cell Cancer ( RCC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 13 Apr 2017

At a glance

  • Drugs Regorafenib (Primary)
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms DAST
  • Sponsors Bayer
  • Most Recent Events

    • 28 Sep 2016 Planned End Date changed from 1 Jan 2017 to 1 Jan 2019.
    • 27 Nov 2015 Planned End Date changed from 1 Jan 2016 to 1 Jan 2017, according to ClinicalTrials.gov record.
    • 18 Feb 2015 Planned End Date changed from 1 Jan 2015 to 1 Jan 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top